This dose-escalation study is aimed at investigating a novel application for artesunate in the treatment of Friedreich ataxia. It will evaluate this novel application of oral artesunate using a surrogate biological marker as primary endpoint in a phase I-II open trial.
Monday, June 14, 2021
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) (ARTEMIS)
ClinicalTrials.gov Identifier: NCT04921930; Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Collaborator: Imagine Institute
Subscribe to:
Posts (Atom)
